Obinutuzumab beta (Bejescin) vs PF-05280586

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Follicular Lymphoma

Shared mechanism: CD20 · full Follicular Lymphoma pipeline

Obinutuzumab beta (Bejescin)

Marketed by Beijing Mabworks Biotech Co., Ltd. and partners

Phase 3 in Follicular Lymphomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

PF-05280586

Marketed by Pfizer

Approved in Follicular Lymphomabiologic (registry-typed, subtype undisclosed)
Reliable signal

NCT02213263 · Phase 3 · completed

The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits.

Reported efficacy

Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26: Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) (met)

Result source: NCT02213263

Results for Follicular Lymphoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Obinutuzumab beta (Bejescin): no structured comparison results are available for Follicular Lymphoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

PF-05280586
Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) NCT02213263 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Obinutuzumab beta (Bejescin)'s landscape · PF-05280586's landscape